American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2020)

Nintedanib: A new player in bladder cancer?

Audrey Abella, 20200323100000

The addition of the potent triple angiokinase inhibitor nintedanib to a standard chemotherapeutic regimen consisting of gemcitabine and cisplatin generated survival benefit in patients with locally advanced muscle invasive bladder cancer (MIBC), according to the results of the NEO-BLADE* trial presented at ASCO GU 2020. However, the study failed to demonstrate improvement in the primary endpoint of pathologic complete response (CR).

Sipuleucel-T improves survival in mCRPC in real world

Elaine Soliven, 20200314000000

The use of sipuleucel-T significantly prolongs overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), regardless of treatment setting, based on real-world data presented at ASCO GU 2020.

CheckMate 214: Nivolumab + ipilimumab benefit maintained at 42 months in aRCC

Elaine Soliven, 20200312000000

Improvements in overall survival (OS) and clinical responses were maintained with the nivolumab (NIVO) + ipilimumab (IPI) combination in patients with advanced renal cell carcinoma (aRCC) at an extended 42-month follow-up, according to updated results of the CheckMate 214* study presented at ASCO GU 2020.

Frontline enfortumab vedotin + pembrolizumab shows promising activity in mUC

Pearl Toh, 20200309190000

A combination therapy of enfortumab vedotin and pembrolizumab shows promising activity, with rapid and durable responses in the first-line setting for patients with metastatic urothelial carcinoma (mUC) ineligible to receive cisplatin, according to updates from the EV-103* study presented at GUCS 2020.

Nivolumab continues positive OS, ORR track record in advanced RCC

Roshini Claire Anthony, 20200305140101

Patients with previously treated advanced or metastatic clear cell renal cell carcinoma (RCC) appear to derive greater overall survival (OS) benefit with nivolumab compared with everolimus, according to final results of the phase III CheckMate 025* trial presented at ASCO GU 2020.

Virtual surveillance well received by testicular cancer patients

Audrey Abella, 20200303100000

An electronic surveillance tool generated better compliance and satisfaction rates than standard in-person care among men with stage 1 testicular cancer, according to the interim results of the WATChmAN* trial presented at ASCO GU 2020.

No benefit from docetaxel after radiotherapy for intermediate- , high-risk prostate cancer

ADT in prostate cancer: Should docetaxel be added?

Pearl Toh, 20200302190000

While combining docetaxel with androgen deprivation therapy (ADT) is known to improve survival for advanced prostate cancer, its role in the setting of adjuvant treatment given after radical radiotherapy plus ADT for the treatment of intermediate- and high-risk prostate cancer was proven otherwise — both in terms of biochemical disease-free survival (BDFS) and quality of life (QoL), according to the SPCG*-13 trial presented at the 2020 Genitourinary Cancer Symposium (GUCS).

Apalutamide plus ADT improves PFS2 in mCSPC

Roshini Claire Anthony, 20200229110101

The addition of apalutamide, a novel androgen receptor inhibitor, to androgen deprivation therapy (ADT) reduced the risk of progression while on first subsequent therapy or death (PFS2) in men with metastatic castration-sensitive prostate cancer (mCSPC), according to exploratory analysis of the phase III TITAN* trial.

Improved pain response with cabazitaxel vs ARTA in mCRPC

Roshini Claire Anthony, 20200227140101

In addition to extending survival, cabazitaxel also improves pain and quality of life (QoL) compared with abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), results from the phase III CARD* trial showed.

$Long-term follow up confirms noninferiority of moderate hypofractionation to conventional RT for prostate cancer$

Long-term follow up confirms noninferiority of moderate hypofractionation to conventional RT for prostate cancer

Audrey Abella, 20200225100000

A moderately hypofractionated radiotherapy (RT) dose schedule was noninferior to conventional RT, according to the 8-year outcomes from the CHHiP* trial presented at ASCO GU 2020.